Year: 2022

SUMMARY OF RECENT PROGRESS in molecular pharming, "Although the various technologies available to Molecular Pharming are broad ranging and flexible, competing technologies are better established, so there needs to be a compelling reason to move into plants. It is most unlikely that plant biotechnology will be the answer for the whole biologics field."" " http://lnkd.in/d33JGyV View in LinkedIn

PLANT BIOREACTOR PROGRESS. By 2009 9 products were on the market, and 19 in clinical trials. By 2013 the commercial pace had accelerated after "the DARPA initiative challenged ... companies to develop strategies for the large-scale manufacture of influenza vaccines, resulting in a successful Phase I clinical trial; in Europe the Pharma-Planta academic consortium gained regulatory approval for a plant-derived monoclonal antibody." http://lnkd.in/dUkpZGwhttp://lnkd.in/d33JGyV View in LinkedIn

SLOW START FOR DRUGS IN PLANTS. Molecular farming has taken almost a quarter of a decade in R&D to develop robust methods, and during this time written over 600 publications, and filed over 100 patent families. In relative terms, this field is still in its infancy, but has seen an increase in pace since 2013. " " http://lnkd.in/dgdAdZj View in LinkedIn

PLANT FACTORIES HAVE BEEN BUSY. "Over the last 10 years, several efficient plant-based expression systems have emerged, and more than 100 recombinant proteins and several other edible vaccines have been produced in a range of different plant species. Plants have many advantages over other production systems particularly in terms of practicality, economy and safety."" " http://www.policyproposalsforindia.com/print_article.php?article_id=235&languageid=1 View in LinkedIn

NEW METHODS AND PIPELINE for plant molecular farming (PMF). "During the last two decades a diverse ... technologies ... were developed in PMF, and thousands of plant-derived biopharmaceutical proteins ... were produced at laboratory and pilot levels, and some of them reached the late stages of commercial and are expected to be marketed soon."" " http://www.omicsgroup.org/journals/2167-0331/2167-0331-2-e136.php?aid=16509 View in LinkedIn

SCALABLE PLANT MOLECULAR FARMING. "The feasibility of precise plant genetic manipulation, high-scale expression of recombinant proteins, rapid and easy scaling up, convenient storage of raw material and less concern of contamination with human or animal pathogens during downstream processing have attracted biotechnologists to PMF, especially plastid and chloroplast engineering for this purpose."" " http://www.omicsgroup.org/journals/2167-0331/2167-0331-2-e136.php?aid=16509 View in LinkedIn

MOLECULAR PHARMING NOW ON THE BRINK OF TAKEOFF. "After two decades of development and academic proofs of principle, a number of recent advances have moved the technology rapidly towards commercialisation. The first products are now being licensed in the USA. The first-in-human clinical trial of a plant derived monoclonal antibody has been performed in Europe. And there has been significant investment into manufacturing facilities around the world."" " http://lnkd.in/d8p-GH2 View in LinkedIn

RISK AND REGULATORY ENVIRONMENT for molecular pharming. Over the past 25 years, molecular pharming has investigated 4 categories of products: (1). Herbicide and pesticide resistant plants; (2). Nutrition improvements (Golden Rice); (3). Industrial proteins (cellulase, trypsin); (4). Pharmaceuticals and vaccines. By April 2011, the EC had approved 30 products. " " http://lnkd.in/dA-gXhH View in LinkedIn

POTENT ABILITY TO MEET DEMAND."Just one farm growing 16,000 acres of safflower could meet the world’s total demand for insulin. But potential cost savings are eliminated under current regulations, set up for GM agricultural crops not pharmaceuticals."" " http://lnkd.in/dykaaMS View in LinkedIn

NFLECTION POINT FOR MOLECULAR FARMING. "Recently, the field has reached an inflection point with the FDA approval of the first prescription biological produced in plant cells. In addition, plant-made production and downstream facilities are being built all over the world, a clear sign of the expansion of plant-based platforms as efficient protein production platforms."" " http://www.ibmcp.upv.es/FGB/cost/home/home.html View in LinkedIn